Compare CTOS & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTOS | NNNN |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | CTOS | NNNN |
|---|---|---|
| Price | $6.31 | $41.73 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 887.2K | 34.6K |
| Earning Date | 03-03-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $1,936,513,000.00 | $6,920,153.00 |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | ★ N/A | $700.97 |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $3.18 | $5.18 |
| 52 Week High | $6.78 | $55.65 |
| Indicator | CTOS | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 67.54 |
| Support Level | $5.82 | $32.93 |
| Resistance Level | $6.25 | $35.40 |
| Average True Range (ATR) | 0.20 | 4.05 |
| MACD | 0.04 | 0.87 |
| Stochastic Oscillator | 83.70 | 100.00 |
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.